• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • PROs
    • Menopause Rating Scale
      • Menopause Rating Scale (MRS) – Languages
    • Aging Male Symptoms Scale
      • AMS – properties as an outcome measure
      • AMS – properties as a screening tool
    • Quality of Sexual Function Scale
      • Quality of Sexual Function Scale
    • Short Term Hormone Effect Scale
      • Short Term Hormone Effect Scale
    • Research team
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Publications

Shapiro Sid, Dinger Jürgen, Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies J Fam Plann Reprod Health Care. 2010; 36:33-38. 10.1783/147118910790291037.
Dinger Jürgen, Do Minh Thai, The risk of venous thromboembolism in OC users: time patterns after initiation of treatment. Pharmacoepidemiology and Drug Safety. 2010; 19:S214-215.
Heinemann Lothar A , Dinger Jürgen, Assmann Anita, Do Minh Thai, Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare" Contraception. 2010; May;81(5):401-7. 10.1016/j.contraception.2009.12.014.
Assmann Anita, Heinemann Klaas, Dinger Jürgen, The safety of oral hormone replacement therapy: Interim results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2010; 19:S31-32.
Bäckström T, Heinemann Klaas, Nyberg S, Hammarbäck S, Definition and prevalence of premenstrual syndromes. Gynaecology Forum. 2009; 14(3).
Cronin Maureen, Schellschmidt Ilka, Dinger Jürgen, Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives Obstet Gynecol. 2009; Sep;114(3):616-22. 10.1097/AOG.0b013e3181b46f54.
Dinger Jürgen, Oral contraceptives and venous thromboembolism: old questions revisited J Fam Plann Reprod Health Care. 2009; 35:211-213. doi: 10.1783/147118909789587385..
Dinger Jürgen, Bardenheuer Kristina, Assmann Anita, International active surveillance study of women taking oral contraceptives (INAS-OC Study) BMC Medical Research Methodology. 2009; 9: 77.. 10.1186/1471-2288-9-77.
Cronin Maureen, Schellschmidt Ilka, Dinger Jürgen, Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives Obstet Gynecol. 2009; 114(3):616-22. 0.1097/AOG.0b013e3181b46f54.
Dinger Jürgen, Cronin Maureen, Schellschmidt Ilka, Do Minh Thai, Westhoff C, Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol. 2009; Sep;201(3):263.e1-9. doi: 10.1016/j.ajog.2009.03.017.
Heinemann Lothar A , Key findings of the IMPACT study. Gynaecology Forum. 2009; 14(3): 9-13..
Damonte Khoury C, Heinemann Lothar A , Assessment of HRQoL and economic impact in patients with premenstrual disorders. Obstet Gynecol. 2009; 111(4) (Supplement Poster abstracts).
  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Interim pages omitted …
  • Page 22
  • Go to Next Page »

sidebar

Search our Publications

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2025 ZEG Berlin

Impressum

Website by Laura Yeffeth.